Cocrystal Pharma, Inc. (COCP)
COCP Stock Price Chart
Explore Cocrystal Pharma, Inc. interactive price chart. Choose custom timeframes to analyze COCP price movements and trends.
COCP Company Profile
Discover essential business fundamentals and corporate details for Cocrystal Pharma, Inc. (COCP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Feb 2012
Employees
11.00
Website
https://www.cocrystalpharma.comCEO
Sam Lee
Description
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
COCP Financial Timeline
Browse a chronological timeline of Cocrystal Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.17, while revenue estimate is $225.00k.
Earnings released on 21 May 2026
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%.
Earnings released on 15 May 2026
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $100.00k , missing expectations by -55.56%.
Earnings released on 14 Nov 2025
EPS came in at -$0.19 surpassing the estimated -$0.22 by +13.64%.
Earnings released on 14 Aug 2025
EPS came in at -$0.20 surpassing the estimated -$0.30 by +33.33%.
Earnings released on 15 May 2025
EPS came in at -$0.23 surpassing the estimated -$0.52 by +55.77%.
Earnings released on 31 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.55 by +41.82%, while revenue for the quarter reached $136.00k .
Earnings released on 13 Nov 2024
EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.
Earnings released on 14 Aug 2024
EPS came in at -$0.53 falling short of the estimated -$0.51 by -3.92%.
Earnings released on 13 May 2024
EPS came in at -$0.39 surpassing the estimated -$0.54 by +27.78%.
Earnings released on 28 Mar 2024
EPS came in at -$0.44 surpassing the estimated -$0.57 by +22.81%, while revenue for the quarter reached $144.00k .
Earnings released on 13 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%.
Earnings released on 14 Aug 2023
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%.
Earnings released on 15 May 2023
EPS came in at -$0.64 falling short of the estimated -$0.59 by -8.47%.
Earnings released on 29 Mar 2023
EPS came in at -$0.55 surpassing the estimated -$0.72 by +23.61%.
Earnings released on 14 Nov 2022
EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%.
Stock split effective on 11 Oct 2022
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Aug 2022
EPS came in at -$0.48 matching the estimated -$0.48.
Earnings released on 11 May 2022
EPS came in at -$0.48 matching the estimated -$0.48.
Earnings released on 23 Mar 2022
EPS came in at -$0.48 matching the estimated -$0.48, while revenue for the quarter reached $5.43k .
Earnings released on 15 Nov 2021
EPS came in at -$0.48 matching the estimated -$0.48.
Earnings released on 16 Aug 2021
EPS came in at -$0.48 matching the estimated -$0.48.
COCP Stock Performance
Access detailed COCP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
